View printer-friendly version

ResApp Health Limited (ASX: RAP), the developer of smartphone medical applications for the diagnosis and management of respiratory disease, is pleased to announce that it has received approval to enrol adult patients at the Wesley Hospital in Brisbane, Australia. The Wesley Emergency Centre (WEC) is one of the largest private emergency departments in Australia.

The WEC will be the second site participating in ResApp’s adult clinical study. The study will gather data from adults presenting to the emergency department with respiratory conditions such as upper respiratory tract infections, bronchitis, pneumonia, asthma and chronic obstructive pulmonary disease. The aim of the study is to demonstrate that ResApp’s technology, shown to be highly accurate for diagnosis of childhood respiratory conditions, can be extended to adults.

Enrolment at the first site, Joondalup Health Campus (JHC), is progressing very well, with 106 subjects (60 confirmed respiratory disease cases and 46 control cases) enrolled since the study was started in December 2015. The study is targeting total enrolment of 400 patients. The clinical data from both the WEC and JHC will be analysed by the team led by Associate Professor Udantha Abeyratne at The University of Queensland with preliminary results expected in the first half of calendar 2016.

– ENDS –

About ResApp Health Limited
ResApp Health Limited, founded in 2014, is developing smartphone medical applications for the diagnosis and management of respiratory disease. The technology is based on machine learning algorithms that use sound alone to diagnose and measure the severity of respiratory conditions without the need for additional hardware. The algorithms were initially developed by The University of Queensland with funding from the Bill and Melinda Gates Foundation. ResApp has a multi-site clinical study underway and preliminary results demonstrated accurate diagnosis of pneumonia, asthma/viral wheeze, bronchiolitis, croup and upper respiratory tract infections in children. Approval has been recently received to extend the study to adults. Markets for ResApp’s technology include telehealth use through partnerships with telehealth service providers, emergency department and regular clinic use by healthcare providers, at-home use by consumers and working with global aid and humanitarian organisations to deliver tools for the developing world.

For more information on ResApp, visit www.resapphealth.com.au

CONTACT
Dr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au

SHAREHOLDER & MEDIA CONTACT
Brian Leedman
Executive Director and VP, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au
ResApp Logo White

ResApp Health Limited
ABN 51 094 468 318
Headquarters: Level 8, 127 Creek St, Brisbane, QLD 4000
Registered Office: Level 24, 44 St Georges Tce, Perth, WA 6000

© 2017 ResApp Health Limited. All Rights Reserved.

CONTACT US

+61 8 6211 5099
+61 8 9218 8875
General Information
Clinical Studies
Investor Relations

      

LEGAL

Terms of Use
Privacy Policy

ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States.

In the United States, ResAppDx is an investigational device and is not available for sale.